STOCK TITAN

Vor Biopharma (VOR) Form 144 shows large June–July sales and an 18,382-share filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Vor Biopharma Inc. (VOR) Form 144 disclosure shows a proposed sale of 18,382 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $36,407.39 and an approximate sale date of 08/11/2025 on NASDAQ. The filing records that these shares were acquired as restricted stock on 08/01/2025 (12,696 shares) and 08/06/2025 (5,686 shares).

The notice also lists multiple sales by Robert Ang in June–July 2025 totaling 1,134,988 shares with gross proceeds of about $2,544,405.10. Several issuer and filer identification fields (including issuer name and filer CIK) are left blank in the form.

Positive

  • Disclosure of broker and exchange used for the proposed sale: Morgan Stanley Smith Barney LLC on NASDAQ
  • Transaction specifics provided: number of shares, aggregate market value, and acquisition dates for the shares proposed to be sold

Negative

  • Extensive recent insider sales reported: 1,134,988 shares sold in June–July 2025 for gross proceeds of about $2,544,405.10
  • Key identification fields missing: the filing content omits the issuer name and filer CIK as presented
  • Filer relationship to issuer not stated in the provided content, limiting context for the sales

Insights

TL;DR: The filing discloses a small proposed sale of recently acquired restricted shares and large prior sales by Robert Ang totaling over one million shares.

The Form 144 identifies a proposed sale of 18,382 shares valued at $36,407.39 to be executed via Morgan Stanley Smith Barney LLC on NASDAQ. The same shares were acquired as restricted stock on 08/01/2025 and 08/06/2025. The document separately reports numerous prior sales by Robert Ang in June–July 2025 aggregating 1,134,988 shares for gross proceeds of approximately $2,544,405.10. These explicit figures are relevant to liquidity and insider selling patterns.

TL;DR: The filing provides clear transaction details but omits issuer and filer identification fields, reducing transparency.

The form documents broker, exchange, acquisition dates, and transaction amounts, which supports regulatory disclosure. However, key fields such as the issuer name and filer CIK are blank in the provided content, and the filer’s relationship to the issuer is not stated. For governance and compliance review, those omissions are noteworthy because they limit immediate verification of insider status and context for the reported sales.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the VOR Form 144 propose to sell?

The filing proposes sale of 18,382 common shares with aggregate market value $36,407.39 via Morgan Stanley Smith Barney LLC on NASDAQ (approximate date 08/11/2025).

When were the shares proposed for sale acquired?

The shares were recorded as restricted stock acquired on 08/01/2025 (12,696 shares) and 08/06/2025 (5,686 shares).

Who sold shares in the past three months according to the filing?

The filing lists multiple sales by Robert Ang in June–July 2025 totaling 1,134,988 shares for gross proceeds of about $2,544,405.10.

Does the Form 144 identify the issuer and filer CIK?

In the provided content the issuer name and filer CIK fields are blank and not populated.

Which broker is named for the proposed sale?

The broker is listed as Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

VOR Latest News

VOR Latest SEC Filings

VOR Stock Data

530.62M
32.32M
39.09%
43.63%
15.62%
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
BOSTON